6α(7α)-Formamido Penicillins and Cephalosporins

Peter H. Milner, Angela W. Guest, Frank P. Harrington, Roger J. Ponsford, Terence C. Smale,* and Andrew V. Stachulski

Beecham Pharmaceuticals, Research Division, Brockham Park, Betchworth, Surrey RH3 7AJ, U.K.

6α(7α)-(Methylthio)penicillins and cephalosporins have been converted into novel antibacterially active 6α(7α)-formamido derivatives by using either mercury(II) acetate and ammonia followed by formylation, or mercury(II) acetate and *N,N*-bis(trimethylsilyl)formamide in a single step.

The naturally occurring 7α-methoxycephalosporins (cephamycins) were discovered in 1971[1] and the consequent observation that the methoxy group stabilised the antibiotics to attack by β-lactamases stimulated considerable research into 6α(7α)-substituted penicillins and cephalosporins.[2] However, even the methoxy moiety, although conferring β-lactamase stability on cephalosporins, only rarely leads to active compounds when present at the 6α-position of penicillins.[3] Other publications have disclosed 6α-aminopenicillins[4] and 7α-aminocephalosporins[5] together with certain *N*-acylated derivatives; all having negligible activity. The formamido substituent has not previously been described, and its presentation in this communication represents a significant advance in the area of 6α(7α)-substitution.

The penicillin V series was selected for initial experiments; the requisite starting material (**2**) being obtained by phenoxy-



(1) R^1 = H, R^2 = SMe
(2) R^1 = $COCH_2OPh$, R^2 = SMe
(3) R^1 = $COCH_2OPh$, R^2 = NH_2
(4) R^1 = $COCH_2OPh$, R^2 = NHCHO
(5) R^1 = $CO_2CH_2CCl_3$, R^2 = SMe
(6) R^1 = $CO_2CH_2CCl_3$, R^2 = NHCHO
(7) R^1 = H, R^2 = NHCHO



(8) R^1 = H, R^2 = SMe
(9) R^1 = $CO_2CH_2CCl_3$, R^2 = SMe
(10) R^1 = $CO_2CH_2CCl_3$, R^2 = NHCHO
(11) R^1 = H, R^2 = NHCHO



(12) R = H
(13) R = COMe



(14) R^1 = CH_2Ph, R^2 = COMe
(15) R^1 = Na, R^2 = COMe
(16) R^1 = Na, R^2 = H

acetyl chloride–pyridine acylation of (**1**).[6] Reaction of (**2**) with equimolar amounts of mercury(II) acetate and ammonia in *N,N*-dimethylformamide (−40 °C warming to 0 °C over 1 h) produced the 6α-aminopenam (**3**) by the normal attack on the intermediate acylimine from the least hindered face.[2] The unpurified product (**3**) was formylated with excess of acetic formic anhydride and pyridine (CH_2Cl_2, 0 °C, 1.5 h) to give the 6α-formamido penicillin V ester (**4**) [62% from (**2**)].† It has been found that the introduction of the formamido substituent can be accomplished in a single step utilising a novel nucleophilic formamide equivalent. Thus reaction of (**2**) with a two-fold excess of *N,N*-bis(trimethylsilyl)formamide[7] [$Hg(OAc)_2$, dimethylformamide, 20 °C, 2 h] gave a 65% yield of (**4**).

The phenoxyacetyl side-chain is experimentally convenient, but one of the least interesting in terms of biological activity. Therefore a route has been devised to the 6α-formamido penicillin nucleus (**7**), which can be coupled to a wide range of different side-chains. The methylthio compound (**1**) was treated with (2,2,2-trichloroethoxy)carbonyl chloride and pyridine to give the protected derivative (**5**), which could be transformed by either the one-step or two-step process to compound (**6**), m.p. 132—134 °C. This was deprotected using zinc powder (5 : 1 tetrahydrofuran–1 M aqueous KH_2PO_4 at pH 4—5)[8] to give the 6α-formamido penicillin (**7**)‡ in an overall yield of up to 52% from (**1**). The 7α-(methylthio)cephalosporanate (**8**)[6] could similarly be protected as a carbamate (**9**) and subjected to a mercury(II) mediated displacement to form the 7α-formamido cephalosporin (**10**). The zinc catalysed deprotection gave in this case a crystalline amine (**11**), m.p. 166—170 °C.

Restricted rotation about the formamide N—C bond allows the two preferred planar conformations to be observed during n.m.r. spectroscopy on the various compounds. The major rotamer is *Z*, which exhibits *J* 1 Hz for N*H*C*H*O, and there is up to 30% of the *E*-rotamer, *J* 11 Hz.[9] A variable temperature proton n.m.r. study was carried out on the cephalosporin nucleus (**11**), and in $(CD_3)_2SO$ solution the CHO signals, which were at δ 8.05 (*Z*) and 8.39 (*E*) at 30 °C, coalesced at 100 °C.

The utility of the 6β(7β)-amino-6α(7α)-formamido compounds can be typified by the coupling to what we have found to be one of the more apt side-chains for biological activity. The D-dihydroxyphenylglycine derivative (**12**)[10] was acetylated (acetic anhydride in tetrahydrofuran–water at pH 6.5—7.0) to give (**13**) and then treated with the 6β-aminopenam (**7**) and *N,N'*-dicyclohexylcarbodiimide to give the penicillin (**14**) in a racemisation-free process. Catalytic hydrogenation (10% Pd/C, tetrahydrofuran) led to the sodium salt (**15**), which deacetylated in aqueous solution at pH 9.0—9.5 to give compound (**16**).[10] This penicillin (BRL 36650) has exceptional activity against Gram-negative bacteria including *Pseudomonas* spp. and is highly resistant to attack by β-lactamases. Full details on antibacterial activity are being published elsewhere.[11]

We thank Prof. R. Ramage and Drs. G. Burton, J. R. Everett, C. J. Moores, and M. J. Pearson for advice and assistance in various aspects of this work.

Note added in proof. A recent paper[12] has described the isolation of 7α-formamido cephalosporins from fermentation of a bacterium.

Received, 23rd July 1984; Com. 1075

† Satisfactory spectroscopic data and mass spectrometric or elemental analyses were obtained for new compounds.

‡ Chromatographically purified (**7**) gave $\nu_{max.}$ ($CHCl_3$) 1780, 1745, and 1695 cm^{-1}; δ($CDCl_3$) 5.35 (0.2 H, s, 5-H), 5.53 (0.8 H, s, 5-H), 6.70 (1 H, br., NH), 8.17 (0.8 H, d, *J* 1 Hz, CHO), and 8.38 (0.2 H, d, *J* 11 Hz, CHO). The crude material was suitable for further reaction, but was best used within a few days when in this state.

References

1 R. Nagarajan, L. D. Boeck, M. Gorman, R. L. Hamill, C. E. Higgens, M. M. Hoehn, W. M. Stark, and J. G. Whitney, *J. Am. Chem. Soc.*, 1971, **93**, 2308.
2 For a recent review see E. M. Gordon and R. B. Sykes, in 'Chemistry and Biology of β-Lactam Antibiotics,' vol. 1, eds. R. B. Morin and M. Gorman, Academic Press, 1982, pp. 199—370.
3 B. Slocombe, M. J. Basker, P. H. Bentley, J. P. Clayton, M. Cole, K. R. Comber, R. A. Dixon, R. A. Edmondson, D. Jackson, D. J. Merrikin, and R. Sutherland, *Antimicrob. Agents Chemother.*, 1981, **20**, 38.
4 D. H. Bremner, M. M. Campbell, and G. Johnson, *J. Chem. Soc., Perkin Trans. 1*, 1976, 1918.
5 B. G. Christensen, L. D. Cama, S. Karady, and M. Sletzinger, U. K. Patent 1 348 984 (to Merck and Co.), 1971.
6 T. Jen, J. Frazee, and J. R. E. Hoover, *J. Org. Chem.*, 1973, **38**, 2857.
7 G. Schirawski and V. Wannagat, *Monatsh. Chem.*, 1969, **100**, 1901.
8 G. Just and K. Grozinger, *Synthesis*, 1976, 457.
9 L. A. La Planche and M. T. Rogers, *J. Phys. Chem.*, 1965, **69**, 3648.
10 P. H. Milner, European Patent 0 071 395 (to Beecham Group), 1983.
11 M. J. Basker, R. A. Edmondson, S. J. Knott, R. J. Ponsford, B. Slocombe, and S. J. White, *Antimicrob. Agents Chemother.*, in the press.
12 P. D. Singh, M. G. Young, J. H. Johnson, C. M. Cimarusti, and R. B. Sykes, *J. Antibiot.*, 1984, **37**, 773.